Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Healthcare
/
Vivos Therapeutics
VVOS
Vivos Therapeutics
Increasing Regulation And Telemedicine Will Limit Future Prospects
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
18 Aug 25
Updated
18 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$2.25
83.6% overvalued
intrinsic discount
18 Aug
US$4.13
Loading
1Y
45.6%
7D
-10.4%
Author's Valuation
US$2.3
83.6% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$2.3
83.6% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-25m
37m
2018
2020
2022
2024
2025
2026
2028
Revenue US$37.3m
Earnings US$2.0m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
21.11%
Healthcare Services revenue growth rate
0.26%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$1.97m
Earnings '28
x
14.82x
PE Ratio '28
=
US$29.15m
Market Cap '28
US$29.15m
Market Cap '28
/
10.64m
No. shares '28
=
US$2.74
Share Price '28
US$2.74
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$2.25
Fair Value '25
